{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T13:22:59Z","timestamp":1781356979631,"version":"3.54.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Torii Pharmaceutical, Eisai, Maruho"},{"name":"Maruho, LEO Pharma, Eisai, AbbVie, Kyowa Hakko Kirin, Taiho Pharmaceutical"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jdsjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Science"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.jdermsci.2019.07.006","type":"journal-article","created":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T19:38:18Z","timestamp":1563910698000},"page":"90-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Anti-IL-17A and IL-23p19 antibodies but not anti-TNF\u03b1 antibody induce expansion of regulatory T cells and restoration of their suppressive function in imiquimod-induced psoriasiform dermatitis"],"prefix":"10.1016","volume":"95","author":[{"given":"Teruo","family":"Shimizu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kamata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saki","family":"Fukaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuko","family":"Fukuyasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamitsu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeko","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamitsu","family":"Ohnishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayoi","family":"Tada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.jdermsci.2019.07.006_bib0005","article-title":"Psoriasis: epidemiology, clinical features, and quality of life","volume":"64","author":"Langley","year":"2005","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.jdermsci.2019.07.006_bib0010","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.clindermatol.2006.07.006","article-title":"Psoriasis and psoriatic arthritis: clinical features and disease mechanisms","volume":"24","author":"Myers","year":"2006","journal-title":"Clin. Dermatol."},{"issue":"6","key":"10.1016\/j.jdermsci.2019.07.006_bib0015","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/jid.2009.59","article-title":"The IL-23\/Th17 axis in the immunopathogenesis of psoriasis","volume":"129","author":"Di Cesare","year":"2009","journal-title":"J. Invest. Dermatol."},{"issue":"4","key":"10.1016\/j.jdermsci.2019.07.006_bib0020","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis--results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"9993","key":"10.1016\/j.jdermsci.2019.07.006_bib0025","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.jdermsci.2019.07.006_bib0030","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"9625","key":"10.1016\/j.jdermsci.2019.07.006_bib0035","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jdermsci.2019.07.006_bib0040","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"Reich","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"issue":"16","key":"10.1016\/j.jdermsci.2019.07.006_bib0045","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"10091","key":"10.1016\/j.jdermsci.2019.07.006_bib0050","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jdermsci.2019.07.006_bib0055","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1038\/nm1518","article-title":"Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells","volume":"12","author":"Loser","year":"2006","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.jdermsci.2019.07.006_bib0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054895","article-title":"Photo(chemo)therapy reduces circulating Th17 cells and restores circulating regulatory T cells in psoriasis","volume":"8","author":"Furuhashi","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jdermsci.2019.07.006_bib0065","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.coph.2010.04.001","article-title":"Vitamin D: modulator of the immune system","volume":"10","author":"Baeke","year":"2010","journal-title":"Curr. Opin. Pharmacol."},{"issue":"3","key":"10.1016\/j.jdermsci.2019.07.006_bib0070","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1189\/jlb.0408249","article-title":"Comprehensive biomarker monitoring in cytokine therapy: heterogeneous, time-dependent, and persisting immune effects of interleukin-10 application in psoriasis","volume":"85","author":"Docke","year":"2009","journal-title":"J. Leukoc. Biol."},{"issue":"2","key":"10.1016\/j.jdermsci.2019.07.006_bib0075","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2174\/1568010043343886","article-title":"Interleukin-10: an important immunoregulatory cytokine with major impact on psoriasis","volume":"3","author":"Asadullah","year":"2004","journal-title":"Curr. Drug Targets Inflamm. Allergy"},{"issue":"1","key":"10.1016\/j.jdermsci.2019.07.006_bib0080","first-page":"17","article-title":"The role of regulatory T cells and anti-inflammatory cytokines in psoriasis","volume":"27","author":"Owczarczyk-Saczonek","year":"2018","journal-title":"Acta Dermatovenerol. Alp. Pannonica Adriat."},{"key":"10.1016\/j.jdermsci.2019.07.006_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdermsci.2018.08.007","article-title":"The vitamin D3 analog, maxacalcitol, reduces psoriasiform skin inflammation by inducing regulatory T cells and downregulating IL-23 and IL-17 production","author":"Hau","year":"2018","journal-title":"J. Dermatol. Sci."},{"issue":"1","key":"10.1016\/j.jdermsci.2019.07.006_bib0090","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1080\/09546630305545","article-title":"Calcitriol shows greater persistence of treatment effect than betamethasone dipropionate in topical psoriasis therapy","volume":"14","author":"Camarasa","year":"2003","journal-title":"J. Dermatolog. Treat."},{"issue":"3","key":"10.1016\/j.jdermsci.2019.07.006_bib0095","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0190-9622(98)70323-8","article-title":"Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement","volume":"39","author":"Lebwohl","year":"1998","journal-title":"J. Am. Acad. Dermatol."},{"issue":"7","key":"10.1016\/j.jdermsci.2019.07.006_bib0100","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1346-8138.2010.01053.x","article-title":"Duration of remission period of narrowband ultraviolet B therapy on psoriasis vulgaris","volume":"38","author":"Karakawa","year":"2011","journal-title":"J. Dermatol."},{"issue":"1","key":"10.1016\/j.jdermsci.2019.07.006_bib0105","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.clim.2014.12.011","article-title":"Deficiency of both L-selectin and ICAM-1 exacerbates imiquimod-induced psoriasis-like skin inflammation through increased infiltration of antigen presenting cells","volume":"157","author":"Mitsui","year":"2015","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jdermsci.2019.07.006_bib0110","doi-asserted-by":"crossref","first-page":"7687","DOI":"10.1038\/ncomms8687","article-title":"Adiponectin regulates psoriasiform skin inflammation by suppressing IL-17 production from gammadelta-T cells","volume":"6","author":"Shibata","year":"2015","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.jdermsci.2019.07.006_bib0115","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.4049\/jimmunol.0802999","article-title":"Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis","volume":"182","author":"van der Fits","year":"2009","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.jdermsci.2019.07.006_bib0120","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.coi.2011.07.012","article-title":"Distinct regulatory CD4+T cell subsets; differences between naive and antigen specific T regulatory cells","volume":"23","author":"Hall","year":"2011","journal-title":"Curr. Opin. Immunol."},{"issue":"11","key":"10.1016\/j.jdermsci.2019.07.006_bib0125","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.2215\/CJN.06620714","article-title":"T cells: soldiers and spies--the surveillance and control of effector t cells by regulatory t cells","volume":"10","author":"Hall","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"7","key":"10.1016\/j.jdermsci.2019.07.006_bib0130","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.4049\/jimmunol.1000148","article-title":"Distinct roles of IL-23 and IL-17 in the development of psoriasis-like lesions in a mouse model","volume":"186","author":"Nakajima","year":"2011","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.jdermsci.2019.07.006_bib0135","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1365-2133.2010.09742.x","article-title":"Foxp3+ regulatory T cells and related cytokines differentially expressed in plaque vs. guttate psoriasis vulgaris","volume":"163","author":"Yan","year":"2010","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.jdermsci.2019.07.006_bib0140","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.clim.2009.11.008","article-title":"Increased Th17 cells are accompanied by FoxP3(+) Treg cell accumulation and correlated with psoriasis disease severity","volume":"135","author":"Zhang","year":"2010","journal-title":"Clin. Immunol."},{"issue":"4","key":"10.1016\/j.jdermsci.2019.07.006_bib0145","doi-asserted-by":"crossref","first-page":"397","DOI":"10.5021\/ad.2010.22.4.397","article-title":"Role of CD4CD25FOXP3 regulatory t cells in psoriasis","volume":"22","author":"Yun","year":"2010","journal-title":"Ann. Dermatol."},{"issue":"1","key":"10.1016\/j.jdermsci.2019.07.006_bib0150","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4049\/jimmunol.174.1.164","article-title":"Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation","volume":"174","author":"Sugiyama","year":"2005","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.jdermsci.2019.07.006_bib0155","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1365-2133.2007.08359.x","article-title":"Functional characterization of CD4+CD25+ regulatory T cells differentiated in vitro from bone marrow-derived haematopoietic cells of psoriasis patients with a family history of the disorder","volume":"158","author":"Zhang","year":"2008","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.jdermsci.2019.07.006_bib0160","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.clim.2013.06.007","article-title":"Psoriasis patients exhibit impairment of the high potency CCR5(+) T regulatory cell subset","volume":"149","author":"Soler","year":"2013","journal-title":"Clin. Immunol."},{"issue":"1","key":"10.1016\/j.jdermsci.2019.07.006_bib0165","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/exd.13403","article-title":"Imiquimod-applied Interleukin-10 deficient mice better reflects severe and persistent psoriasis with systemic inflammatory state","volume":"27","author":"Jin","year":"2018","journal-title":"Exp. Dermatol."},{"issue":"4","key":"10.1016\/j.jdermsci.2019.07.006_bib0170","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.immuni.2015.08.019","article-title":"Differential Roles for Interleukin-23 and Interleukin-17 in Intestinal Immunoregulation","volume":"43","author":"Maxwell","year":"2015","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.jdermsci.2019.07.006_bib0175","doi-asserted-by":"crossref","first-page":"999","DOI":"10.4049\/jimmunol.1400504","article-title":"Effector T cells boost regulatory T cell expansion by IL-2, TNF, OX40, and plasmacytoid dendritic cells depending on the immune context","volume":"194","author":"Baeyens","year":"2015","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.jdermsci.2019.07.006_bib0180","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/jid.2011.139","article-title":"Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin","volume":"131","author":"Bovenschen","year":"2011","journal-title":"J. Invest. Dermatol."},{"issue":"6","key":"10.1016\/j.jdermsci.2019.07.006_bib0185","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1182\/blood-2008-01-133967","article-title":"Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells","volume":"112","author":"Koenen","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jdermsci.2019.07.006_bib0190","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1136\/annrheumdis-2013-204228","article-title":"Regulatory T cells in rheumatoid arthritis showed increased plasticity toward Th17 but retained suppressive function in peripheral blood","volume":"74","author":"Wang","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jdermsci.2019.07.006_bib0195","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molimm.2017.01.008","article-title":"IL-12 and IL-23 modulate plasticity of FoxP3(+) regulatory T cells in human Leprosy","volume":"83","author":"Tarique","year":"2017","journal-title":"Mol. Immunol."},{"issue":"1","key":"10.1016\/j.jdermsci.2019.07.006_bib0200","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4049\/jimmunol.179.1.154","article-title":"Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells","volume":"179","author":"Chen","year":"2007","journal-title":"J. Immunol."}],"container-title":["Journal of Dermatological Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181119302130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181119302130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T04:49:39Z","timestamp":1760330979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923181119302130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0923181119302130"],"URL":"https:\/\/doi.org\/10.1016\/j.jdermsci.2019.07.006","relation":{},"ISSN":["0923-1811"],"issn-type":[{"value":"0923-1811","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-IL-17A and IL-23p19 antibodies but not anti-TNF\u03b1 antibody induce expansion of regulatory T cells and restoration of their suppressive function in imiquimod-induced psoriasiform dermatitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Dermatological Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdermsci.2019.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}